ArticleBMC gastroenterology2025
Relationship between gut microbiota dysbiosis and bile acid in patients with hepatitis B-induced cirrhosis.
Article in BMC gastroenterology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Interplay between viral infections and gut microbiota dysbiosis: Mechanisms and therapeutic potential.World journal of gastroenterology · 2026Review
- Advances in research on the effects of bile acids and their receptors on intestinal function.Frontiers in nutrition · 2026Review
- Gut-Brain Axis and Bile Acid Signaling: Linking Microbial Metabolism to Brain Function and Metabolic Regulation.International journal of molecular sciences · 2025Review
- Metaflammation's Role in Systemic Dysfunction in Obesity: A Comprehensive Review.International journal of molecular sciences · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
backgroundDysbiosis of the gut microbiota is a significant factor influencing the progression of hepatitis B-related cirrhosis (HBC). Bile acid (BA) metabolism is increasingly recognized as a key participant in the liver-gut microbiota axis.
methodsA total of 46 patients with HBC and 33 healthy adults were enrolled in this study. The HBC patients were divided into a BA-normal group and a BA-high group. Fecal samples were collected from patients under the conditions of their daily diet, and the 16 S rRNA test was performed for each sample.
resultsCompared with that in healthy adults, the alpha diversity of the gut microbiota in HBC patients significantly changed, with a decrease in beneficial microbiota and an increase in opportunistic pathogens. Notably, Bacilli, Enterobacteriales, Streptococcaceae, Veillonella and Lactobacillales were significantly increased in BA-high patients, whereas Clostridia and Clostridiales were significantly decreased. Akkermansiaceae abundance was reduced in the HBC group, and Lactobacillales was markedly enriched in HBC patients, with its abundance proportionally increasing with increasing BA.
conclusionThese findings provide critical insights for investigating the gut microbiota‒BA crosstalk in HBC, facilitating the discovery of novel biomarkers for disease monitoring and the development of microbiota-targeted therapeutic strategies modulating BA metabolism to intervene in HBC progression.
trial registrationThis study was registered in the Chinese Clinical Trial Registry (ChiCTR2400090990) on October 17, 2024 (retrospectively registered).
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.